<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024424</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 60413</org_study_id>
    <nct_id>NCT03024424</nct_id>
  </id_info>
  <brief_title>Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD</brief_title>
  <official_title>Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this study are:&#xD;
&#xD;
      To assess the impact of genetic testing based on how it alters behaviors, to assess the&#xD;
      utility of serum biomarker measurement in combination with genetic testing, to assess the&#xD;
      utility of genetic counseling in personal analysis of risk for age-related macular&#xD;
      degeneration (AMD), and to assess the impact of presymptomatic genetic testing for choroidal&#xD;
      neovascularization (CNV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking is applicable to risk of age-related macular degeneration, not to intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotenoid levels in the skin</measure>
    <time_frame>Twelve months</time_frame>
    <description>Carotenoid levels in the skin are measured non-invasively at baseline and again at 12 months. Carotenoid levels are a biomarker of fruit and vegetable intake.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in carotenoid levels in the eyes</measure>
    <time_frame>Twelve months</time_frame>
    <description>Carotenoid levels in the eyes are measured non-invasively at baseline and again at 12 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <condition>Genetic Counseling</condition>
  <arm_group>
    <arm_group_label>Early disclosure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early disclosure group receives results of genetic testing at Week 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late disclosure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Late disclosure group receives results of genetic testing at final study visit (Month 12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Early disclosure</intervention_name>
    <arm_group_label>Early disclosure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Late disclosure</intervention_name>
    <arm_group_label>Late disclosure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian (this particular genetic test is only validated in Caucasians) Participants&#xD;
             can have a positive family history of AMD but this is not necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with a personal history of AMD are not eligible. Non-caucasian individuals&#xD;
             are not eligible. Employees of the Moran Eye Center are not eligible.&#xD;
&#xD;
          -  Individuals with a personal history of previous AMD genetic risk testing are not&#xD;
             eligible.&#xD;
&#xD;
          -  Individuals with a major psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S. Bernstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Moran Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah John A. Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Paul S. Bernstein</investigator_full_name>
    <investigator_title>Professor, Ophthalmology/Visual Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

